Monopar Therapeutics Inc
NASDAQ:MNPR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Cash Equivalents
Monopar Therapeutics Inc
Cash Equivalents Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Cash Equivalents
$7.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is Monopar Therapeutics Inc's Cash Equivalents?
Cash Equivalents
7.8m
USD
Based on the financial report for Mar 31, 2024, Monopar Therapeutics Inc's Cash Equivalents amounts to 7.8m USD.
What is Monopar Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
6%
Over the last year, the Cash Equivalents growth was 36%. The average annual Cash Equivalents growth rates for Monopar Therapeutics Inc have been -33% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
